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As the designs of polymer systems used to deliver nucleic acids continue to evolve, it is becoming increasingly
apparent that the basic bulk manufacturing techniques of the past will be insufficient to produce
polymer-nucleic acid nanocomplexes that possess the uniformity, stability, and potency required for their
successful clinical translation and widespread commercialization. Traditional bulk-prepared products are
often physicochemically heterogeneous and may vary significantly from one batch to the next. Here we show
that preparation of bioreducible nanocomplexes with an emulsion-based droplet microfluidic system
produces significantly improved nanoparticles that are up to fifty percent smaller, more uniform, and are less
prone to aggregation. The intracellular integrity of nanocomplexes prepared with this microfluidic method is
significantly prolonged, as detected using a high-throughput flow cytometric quantum dot Fo¨rster resonance
energy transfer nanosensor system. These physical attributes conspire to consistently enhance the delivery of
both plasmid DNA and messenger RNA payloads in stem cells, primary cells, and human cell lines.
Innovation in processing is necessary to move the field toward the broader clinical implementation of safe
and effective nonviral nucleic acid therapeutics, and preparation with droplet microfluidics represents a step
forward in addressing the critical barrier of robust and reproducible nanocomplex production.
A
s the range of known potential targets for therapeutic molecular intervention expands, nucleic acid-based
drugs are poised to play amore prominent role in the treatment of inherited and acquired human diseases.
Recent clinical trials hint at the therapeutic potential of gene therapy, but this potential remains stymied
by the dearth of safe and efficient delivery systems1–4. One approach has been to use cationic polymers to condense
nucleic acids into nanocomplexes (polyplexes) that facilitate cellular uptake and prevent degradation en route to
target cells. While tremendous creativity and innovation in carrier design have produced very sophisticated
polymeric gene delivery systems, nonviral methods remain prohibitively inefficient for most applications5–9.
The circulatory residence time, cellular uptake, transfection efficiency, and toxicity of nanoparticles all depend
to some extent on physicochemical attributes such as size, stability, shape, and charge10,11. However, the physical
aspects of polyplex production, and their role in determining these properties, have been largely overlooked.
The assembly of nanocomplexes by charge neutralization is a process that occurs in milliseconds12,13. While
preparation in bulk formats by pipetting, shaking, or oscillatory mixing is convenient, these methods are poorly
suited to reproducibly generate uniform particles given the kinetically determined nature of the formation
process14. Irreproducibility is typical; slight perturbations of bulk mixing protocols often yield particles of varied
properties. The poor quality of these polyplexes exacerbates the challenge of establishing precise structure-
function relationships and precludes mechanistic understandings of the gene transfer process, as subpopulations
of particles may be responsible for observed phenomena. The inability to manufacture nonviral delivery systems
in a reproducible and scalable manner also hinders their clinical translation. As the field has begun to consider the
physical control of nanoparticle assembly as an opportunity for innovation, several novel techniques have
emerged15–17. Top-down nanoimprinting systems produce nanoparticles with defined shape and size that have
proven valuable in deconvoluting the mechanistic effects of such characteristics. However, the rapid reaction
kinetics, aqueous conditions, and temperature sensitivity of polyplex assembly favor microfluidic approaches,
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which have included both monophasic laminar flow systems and
emulsion-based designs13,18–22. The former suffer from flocculation
at high concentrations, while the latter have been used successfully
in production of both lipoplexes and polyplexes. Here, we have
used an emulsion-based microfluidic system to confine the synthesis
of polyplexes to picoliter sized water-in-oil droplets. This system
for microfluidics assisted confinement (MAC) enables the mixing
of polyelectrolyte components to proceed more rapidly so that poly-
plexes are formed under equilibrium conditions.
For such a system to be broadly useful, it must perform well with
different payloads and across multiple cell types. Plasmid DNA is the
predominant payload in gene delivery, but messenger RNA elimi-
nates the requirement of nuclear delivery and more easily produces
transgene expression in some slowly dividing or post-mitotic cells.
However, substitution of the payload may not be trivial, as there is
mounting evidence that polycations interact differently with DNA
than they do with RNA23. Double stranded DNA is a stiffer molecule
with a longer persistence length than single-stranded messenger
RNA, and shorter nucleic acids may diminish the effects of molecu-
lar chain entanglement. In line with our aim to establish the broad
potential of MAC to control polyplex self-assembly, in this study we
utilized a promising bioreducible linear poly(amido amine) gene
carrier and hypothesized that DNA polyplexes prepared with
MAC would be more homogeneous and more potent. Next, we
tested whether the benefits of MAC preparation would also apply
to complexes loaded with RNA payloads and probed their potency in
multiple translationally relevant and difficult-to-transfect target cell
types. We evaluated the products in terms of size, polydispersity, zeta
potential, binding stability, aggregation behavior, amount of
unreacted polyion species, and transfection efficiency. Through the
use of a quantum dot Fo¨rster resonance energy transfer (QD-FRET)
based assay, we furthermore quantified the cellular uptake and intra-
cellular unpacking of MAC polyplexes in an attempt to correlate
their performance with their ability to overcome these two specific
rate-limiting barriers to delivery. This study helps bridge a void in
the structure-function understanding of gene delivery by dem-
onstrating how physical polyplex attributes dictated by their pre-
paration can influence intracellular behavior and transfection
efficiency. Together, the results of these studies demonstrate that
nonviral gene delivery can be improved not only by chemical design
and optimization, but also through innovation in processing and
preparation techniques.
Results
Polyplex preparation and physical characterization. We prepared
polyplexes loaded with either plasmid DNA or messenger RNA using
the bioreducible linear poly(amido amine) poly(CBA-ABOL) in bulk
and MAC formats (Figure 1). We selected this gene carrier for its
high efficiency, low toxicity, and ability to deliver multiple types of
nucleic acids24,25. Following a systematic optimization of bind-
ing characteristics, DNA and RNA polyplexes were synthesized
exclusively at polymer5nucleic acid mass ratios of 4551 and 6051,
respectively (Supplementary Figure 1). In both cases, preparation
with MAC resulted in the production of smaller and more
monodispersed polyplexes. The Z-average diameters of MAC poly-
plexes were 40–50% smaller than those of bulk controls immediately
following synthesis (Figure 2A). The width of the size distribution
was also significantly reduced, as evidenced by similar reductions in
the polydispersity index (PDI). To quantify the propensity of the pro-
ducts to aggregate, we additionally measured changes in polyplex size
at five-minute intervals over the course of a typical four-hour
transfection period (Figure 2B). Bulk polyplexes began to aggregate
immediately, and continued to grow in size throughout the period
studied. In contrast, MAC polyplexes exhibited a much higher degree
of colloidal stability and remained approximately unchanged in size
throughout the measurement period. The surface charge density of
the polyplexes, represented by the zeta-potential, was also considered
(Figure 2C). MAC polyplexes exhibited lower zeta-potentials,
suggesting more complete charge neutralization or the presence of
a diminished polymer corona, either of which may contribute to
improved colloidal stability by reducing charge imbalances and
intraparticle heterogeneity26. The physical profiles of nanoparticles
are important, as the putative rate-limiting barriers associated with
the low efficiency of nonviral vectors include cellular binding and
uptake, endosomal escape, cytosolic transport and unpacking,
nuclear entry, and transcriptional processing. Physical particle pro-
perties determine the degree to which particles are able to overcome
each of these hurdles. Knowing that MAC preparation yields smaller,
more monodispersed, and less positively charged DNA and RNA
polyplexes, we next examined complex binding stability and the
final disposition of the polymer component following the complexa-
tion reaction.
Analysis of complexation and binding. A common shortcoming of
bulk preparation is the failure to exhaust the molecular reactants
Figure 1 | Design of microfluidic chip and gene carriers. (A) A microfluidic cross-flow droplet generator chip is used to produce emulsified aqueous
droplets containing the polymeric gene carrier and nucleic acids. While confined to these , 100 pL droplets, the polyions self-assemble into
nanocomplexes. Following collection and disruption of the droplets, the polyplexes are collected and used directly. Channel dimensions are 50 mm
(width) 3 35 mm (height) (B) Chemical structure of p(CBA-ABOL) (C) Chemical structure of p(CBA-ABOL90/BDA10).
www.nature.com/scientificreports
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due to the rapid complexation under chaotic and heterogeneous
conditions. This is problematic because excess unreacted polymer
has been shown to contribute to polyplex aggregation and cytoto-
xicity during transfection27. To quantify the amount of unreacted
polymer left in solution, we prepared 10 mg nucleic acid doses of
polyplexes with p(CBA-ABOL) and Cy5-labeled p(CBA-ABOL90/
BDA10) in a 451 ratio. Following preparation, we removed the
polyplexes by centrifugation. The supernatant was lyophilized,
reconstituted in 100 mL complexation buffer, and transferred to a
96-well plate for quantification of the remaining excess polymer.
MAC preparation significantly reduced the fraction of polymer left
unreacted (Figure 3A). To further probe the composition of MAC
polyplexes, we then measured the binding stability between polymer
and payload using a fluorescence-based binding assay. PicoGreen
and RiboGreen are cationic dyes that fluoresce upon intercalation
with DNA or RNA, respectively. When added in increasing
concentrations to intact polyplexes, they compete with the gene
carrier to bind nucleic acids. As complexes are disrupted by the
competition and the shielding of the nucleic acids by the polymer
is diminished, the fluorescent signal of the dye intensifies accordingly
with little background signal from unbound reagent. Consequently,
the increase in fluorescence indicates the level of decomplexation
between nucleic acid and polymer. As seen in Figure 3B and 3C,
the MAC polyplexes remained comparatively more intact as
increasing concentrations of competitor were introduced. At the
maximum competitor concentrations, bulk controls were signifi-
cantly disrupted while MAC polyplexes remained resistant. Such
increased binding stability and resistance to competitive disruption
may lead to better protection from premature degradation and a
more sustained intracellular release of payload. However, this
relationship depends on the gene carrier involved; some polymers
bind nucleic acids too tightly to efficiently deliver them to the
nucleus28. While this is less likely to occur with bioreducible and
biodegradable carriers such as the one used here, further analysis
was necessary to demonstrate that increased complexation and
tighter binding leads to improved activity.
Figure 2 | Size and charge characterization of nanocomplexes. (A) Size frequency distributions by intensity of polyplexes measured by dynamic light
scattering immediately following preparation, with Z-average diameters indicated with black lines. Z-average diameter6 SEM and polydispersity indices
are reported below for bulk and MAC preparations of both pDNA and mRNA polyplexes (n 5 5 each). (B) Aggregation propensity shown as the Z-
average diameter over time (n5 5 each,measured at 5minute intervals) (C) Zeta potential for each type of polyplex, shown asmean6 SEM and analyzed
with student’s t-test (* p , 0.05) (n 5 5 each).
Figure 3 | Unreacted polymer and binding stability of nanocomplexes. (A) The amount of unreacted Cy5-labeled polymer remaining in the product
from each method was quantified after removal of pDNA polyplexes by centrifugation. (B), (C) Binding stabilities of pDNA and mRNA polyplexes
weremeasured using PicoGreen and RiboGreen competition assays, respectively. Fluorescence was corrected for background signal and normalized such
that polymer-free controls 5 1.0 arbitrary units (AU). Data is shown as mean 6 SEM (n 5 3 each).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 3155 | DOI: 10.1038/srep03155 3
Transfection efficiency and cellular uptake. The most critical aspect
of polyplex performance is transfection efficiency. We tested both
DNA and RNA polyplexes in four cell types that spanned the most
common target classes for gene delivery applications. Primary mouse
embryonic fibroblast (PMEF) cells were selected for their prevalence
in the cellular reprogramming and induced pluripotent stem cell
fields. Human mesenchymal stem cells (hMSC) were included to
represent primary human adult stem cells. HepG2 human hepato-
cellular carcinoma cells were tested due to their characteristic low
transfectability and the importance of hepatocytes as a destination for
gene delivery systems designed to target the liver. Lastly, HEK293
human embryonic kidney cells were chosen to compare with the large
body of prior work. At 24 hours following delivery to the four
different cell types, the transfection efficiency polyplexes loaded
with 1 mg pDNA or mRNA encoding GFP was assessed with
fluorescence microscopy and quantified by flow cytometry. In each
case, transfection withMAC polyplexes resulted in a larger fraction of
cells expressing the GFP reporter protein (Figure 4A and 4B). The
gains ranged from 6 to 31 percent more cells transfected, and were
particularly significant in difficult-to-transfect cell types such as
HepG2 and hMSC. Several different doses of polyplexes were
delivered to HEK293 cells to verify that this result was not dose-
dependent, and the improvement persisted across the range of
doses (Figure 4C). In some applications, the total level of transgene
produced may be more important than the number of individual cells
transfected. To measure gross transgene expression, 1 mg doses of
pDNA encoding luciferase was delivered to each of the four cell
types. In each case, transfection with MAC polyplexes resulted in
1.9 to 6.8-fold higher total expression as quantified by lumine-
scence detection (Figure 4D). Cytotoxicity comparisons are not
shown, as poly(CBA-ABOL) is effectively non-toxic at single dose
levels (Supplementary Figure 3).
To elucidate the mechanistic relationship between the physical
attributes of MAC polyplexes and their improved performance, we
focused on two of the primary rate-limiting barriers of nonviral gene
delivery: cellular uptake and intracellular unpacking. Although the
optimal dimensions of particles for cellular uptake remain a topic of
debate, endocytosis is believed to be a size-dependent process29. It
follows that the most straightforward means for MAC to improve
transfection would be through an increase in cellular uptake due to
the smaller size ofMACpolyplexes.Wemeasured cellular uptake in a
high-throughput manner using flow cytometric detection of inter-
nalizedQD-labeled pDNA. Bulk andMACpolyplexes were delivered
to HEK293 cells, which were fixed to arrest endocytosis at defined
timepoints and washed with heparin to remove any remainingmem-
brane-associated complexes. Flow cytometry was used to detect the
percentage of cells containing the labeled plasmid at each point, as
well as the mean fluorescence signal that correlates with the total
mass of internalized plasmid. We observed no difference in uptake
between bulk andMACprepared polyplexes over the time course of a
typical transfection period by either metric (Figure 5B and 5C).
While the size of MAC polyplexes is reduced, the difference may
not be sufficient to alter the rates or modes of endocytosis. If
increased uptake is not responsible for the functional benefits of
MAC polyplexes, the improvements likely arise from a subsequent
process.
Intracellular behavior of nanocomplexes.Next, we used QD-FRET
detection to examine the intracellular decondensation rates of MAC
polyplexes. Fo¨rster resonance energy transfer (FRET) is a technique
Figure 4 | Transfection efficiency in four cell types. (A) Fluorescencemicrographs of four cell types transfectedwith bulk orMACpolyplexes loadedwith
1 mg of either pDNA ormRNA encoding GFP. Scale bar5 50 mm(B)Quantification of GFP transfection efficiency with flow cytometry (p, 0.05 in each
case) (C) Transfection efficiency in HEK293 cells across a range of doses confirms that the increased transfection by MAC polyplexes is not dose-
dependent. (D) Quantification of total transgene expression following transfection with pLuc DNA complexes.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 3155 | DOI: 10.1038/srep03155 4
that provides the unique ability to resolve molecular interactions
beyond the diffraction limit of conventional microscopy. When
FRET occurs, a donor fluorophore excites an acceptor via a nonra-
diative dipole–dipole interaction if they are sufficiently close (within
, 10 nm). This so-called ‘molecular ruler’ can be used to determine
distances between labeled molecules inside cells, including gene
carriers and nucleic acids30. Fluorescence colocalization methods
do not offer the requisite sensitivity to precisely detect the onset of
particle dissociation, to differentiate between molecules that are
interacting or simply adjacent, or allow for high-throughput ana-
lysis. Furthermore, conventional fluorophores suffer from chemical
and photodegradation, photobleaching and broad spectra. Conver-
sely, semiconductor QDs possess broad absorption spectra, tunable
narrow emission spectra, resistance to bleaching and chemical
degradation, and large energy separation between excitation and
emission eliminating the need for ratiometric disambiguation. In
our case, excited QD donors transfer energy to Cy5 acceptors as
long as polyplexes containing both constituents remain intact.When
the complexes dissociate, the energy donors and acceptors become
separated and the FRET-mediated Cy5 emission is lost, giving a
precise digital indication of polyplex dissociation (Figure 5A). It
has been previously shown that QD-FRET labeling does not
significantly alter the physical properties or bioactivity of poly-
plexes28. We again chose flow cytometric detection to acquire
precise temporal data on the intracellular unpacking rates. It was
assumed that at the first time point, most of the polyplexes would
still be intact, with FRET-mediated emission signal deteriorating
over time as polyplexes unpacked. The values at the first point
were thus chosen to represent maximum complexation. Over
24 hours following transfection, MAC polyplexes remained intact
much longer than the more quickly unpacked bulk samples
(Figure 5D). For example, by the six-hour time point, the QD-
FRET signal for bulk polyplexes had decayed to less than half of its
maximum. Meanwhile, the MAC signal still exceeded 75 percent of
its initial value. This prolonged intracellular stability may provide
better payload protection prior to endosomal escape, as well as a
more sustained release of the nucleic acid that may increase the
chances of nucleic acids penetrating the nucleus during cell
division. This flow cytometric population-level rate quantification
shows that the increased extracellular stability of MAC polyplexes
translates to the intracellular domain. This study therefore iden-
tifies a mechanistic relationship whereby controlling the physical
assembly of nanocomplexes with MAC enables the modulation of
polyplex properties to achieve improved nonviral gene transfer.
Discussion
The development of safe and effective gene carriers is critical to the
eventual success of nonviral gene therapy, and optimizing the assem-
bly processes used to prepare polymer-nucleic acid nanocomplexes is
one strategy to move toward this goal. We have reported the benefits
of a microfluidic approach to better control the preparation of poly-
plexes and to produce more uniform and more potent delivery sys-
tems. While polymer-DNA nanocomplexes have been synthesized
by microfluidics, to our knowledge this is the first example of the
production of polymer-RNA nanocomplexes with a droplet-based
microfluidic approach, as well as the first time that QD-FRET has
been used in combination with flow cytometry to quantify the intra-
cellular unpacking of polymer-DNA nanocomplexes. We have
demonstrated that MAC polyplexes exhibit significant and consist-
ent decreases in size, zeta potential, and polydispersity relative to
complexes synthesized by traditional bulk mixing. Both DNA- and
RNA-loaded nanocomplexes exhibit increased colloidal and binding
stability, as quantified by fluorescence-based competitive binding
assays. Transfection was significantly improved in a broad range of
cell types, in terms of both the number of cells transfected and gross
transgene expression. We ascribed this improvement in part to a
Figure 5 | Cellular internalization and intracellular unpacking. (A) Labeling scheme to detect uptake and unpacking using QD-FRET. Biotinylated
pDNAwas labeled with QD energy donors, while the polymer was functionalized with the Cy5 QD-FRET acceptor. QD-FRET emission is detected while
polyplexes are intact. Following unpacking, QD-FRET signal is lost and separate donor and acceptor emissions are recovered. (B), (C) Cellular
internalization was quantified by measuring the fluorescence signal of QD-labeled pDNA in cells at different time points using flow cytometry. No
significant difference was observed in the rates of uptake by cell number of normalized geometric mean fluorescence. (D) Intracellular unpacking was
quantified by measuring the QD-FRET signal in cells at different time points using flow cytometry. Bulk controls unpacked more rapidly than MAC
polyplexes (p , 0.05 for all timepoints after 300 min).
www.nature.com/scientificreports
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more gradual release of nucleic acids offered by MAC nanocom-
plexes, evidenced by the slower decline of intracellular QD-FRET
emission. MAC preparation not only improves the biological per-
formance of polyplexes, butmay also help establish clearer structure-
function relationships to guide future carrier design and advance
nonviral gene therapy.
Methods
Polymer synthesis and labeling. Poly(CBA-ABOL) was synthesized byMichael-type
polyaddition of 3.67 g N,N-cystaminebisacrylamide (CBA) (Polysciences,
Warrington, PA) and 1.26 g 4-amino-1-butanol (ABOL) (Sigma-Aldrich, Saint
Louis, MO) as described by Lin et al31. The reaction product was purified by dialysis
(3.5 kDa cutoff) in acidic deionized water (pH 4) and then lyophilized. The polymer
was collected in its HCl-salt form (1.63 g, 33% yield). Due to the absence of primary
amines on poly(CBA-ABOL) for conjugation of fluorescent labels, we also
synthesized the copolymer poly(CBA-ABOL90/BDA10) by substituting 10% N-Boc-
1,4-butanediamine (BDA) for 4-amino-1-butanol in the polymerization.
Deprotection of the Boc-protected amino groups in the copolymers was performed in
a mixture of methanol/trifluoroacetic acid (10 mL, 1/1, v/v) overnight prior to
dialysis. The primary amines on the BDA side chains of the copolymer were then
functionalized with Cy5-NHS (Amersham Biosciences, Piscataway, NJ) fluorescent
dye and purified again by dialysis. Labeled polymer was used in a 154 ratio with
unlabeled p(CBA-ABOL) to maximize the efficiency of the QD-FRET sensor. The
incorporation of fluorescent labels did not affect the size, zeta potential, or
transfection efficiency of polyplexes. Both polymer structures were validated by
Matrix Assisted Laser Desorption/Ionization (MALDI) mass spectrometry and 1H
NMR (not shown).
Nucleic acid production and labeling. Plasmids pDNA (pmaxGFP, Lonza,
Switzerland), pLuc (VR1255 Luciferase, Vical, San Diego, CA) and pT7-EGFP-N1
(gift from David Boczkowski, Duke University) were propagated in Escherichia coli
DH5a (Invitrogen, Carlsbad, CA) and purified with EndoFree Plasmid Mega and
Maxi kits (Qiagen, Germantown, MD). Following linearization, in vitro transcription
was performed on T7-EGFP-N1 with the mMESASGE mMACHINE T7 kit
(Invitrogen) to generate mRNA encoding GFP. To enable attachment of fluorescent
labels, pDNA was biotinylated as described by the manufacturer (Label IT Biotin,
Mirus Bio, Madison, WI) but scaled to have approximately one to two biotin labels
per molecule, then purified from unreacted reagents by ethanol precipitation.
Biotinylated samples were reacted with streptavidin-functionalized quantum dots
(QDs, Qdot 605 ITK, Invitrogen) as described previously32. Nucleic acid was added in
excess toQDs to ensure no unreactedQDs remained. TheQDswerematchedwith the
Cy5 used to label the polymer to comprise a quantum dot Fo¨rster resonance energy
transfer (QD-FRET) pair that was used to assess the intracellular binding status of
polyplexes.
Fabrication and operation of microfluidic device. Cross-flow droplet generators
were fabricated using conventional soft lithography33,34. PDMS prepolymer was cast
and cured on an SU-8 3025 (MicroChem, Newton, MA)master (Transparency mask,
CAD/Art Services, Bandon, OR), which produced a channel height of approximately
35 mm. PDMS prepolymer (Sylgard 184 Silicone Elastomer Kit, Dow Corning,
Midland, MI) was prepared in a 1051 (base5curing agent) ratio and cured at 65uC for
1 hr. The cured PDMS was then excised, punched with through-holes to accept
fluidic connections, and bonded to glass cover slips using a thin layer of spin-coated
PDMS to create channels surrounded by PDMS on all sides. The fully assembled chips
were then left in an oven at 95uC overnight to promote complete bonding.
Prior to use, the microfluidic channels were flushed with the oil phase solution for
30minutes to ensure wetting. To generate polyplexes, two syringe pumps (PHD2000,
Harvard Apparatus, Holliston, MA) were used to infuse the oil/surfactant mix and
aqueous reagents independently through syringe tubing adapters (Hamilton, Reno,
NV). The oil phase consisted of FC-40 fluorocarbon oil (3 M, St. Paul, MN) and 2%
PEGylated fluorosurfactant (EA Surfactant RainDance Technologies, Lexington, MA
or PicoSurf 1, Dolomite Microfluidics, Royston, UK). Flow rates were set at 7.5 mL
min21 for the oil phase input and 2.5 mL min21 for each of the three aqueous inputs.
Water-in-oil droplets (,100 pL) were generated at the channel junction, where the
polymer and nucleic acid solutions, separated by a buffer channel, were introduced to
the continuous oil phase. Polyplexes self-assembled while confined to the droplets,
while mixing of their components was enhanced by the inclusion of a serpentine
channel segment35. MAC polyplexes were collected by breaking the droplets (Droplet
Destabilizer, RainDance Technologies) and used directly from the aqueous super-
natant for subsequent characterization or cellular investigation without any further
purification. Bulk preparation was performed following published protocols31.
Briefly, polyplexes were prepared by adding a complexation buffer solution (20 mM
HEPES, 5 wt% glucose, pH 7.4) of polymer (844 mgmL21 for DNA, 1125 mgmL21 for
RNA) to a complexation buffer solution of nucleic acid (75 mg mL21) followed
immediately by 20 seconds of vortex mixing. Reaction sizes ranged from 5 to 15 mg of
nucleic acid. The presence of the reagents used for MAC droplet generation did not
significantly affect the actvity of bulk products (Supplementary Figure 3). Identical
reagent solutions and concentrations were introduced into the droplet generator to
produce MAC polyplexes.
Nanocomplex characterization. Polyplex sizes and zeta potentials were measured
with a Zetasizer NanoZS-90 (Malvern Instruments, Southborough, MA). Polyplexes
were assayed at a nucleic acid concentration of 15 mg mL21 for size measurements.
Measurements of five independent samples were performed at 25uC using a 90u
scattering angle. To assess aggregation kinetics, measurements were repeated at five-
minute intervals over a four-hour period. Size is reported as the Z-average diameter,
or intensity weighted mean hydrodynamic diameter. Zeta-potential measurements
were performed on five independent samples at a final DNA concentration of 3 mg
mL21 using a capillary flow cells (Malvern Instruments) in complexation buffer at pH
7.4 and 25uC.
Cell culture and transfection. For all cell culture experiments, 20,000 cells cm22 cells
were seeded 24 hours prior to transfection in 24-well TCPS plates (BD, Franklin
Lakes, NJ) and cultured at 37uC and 5% CO2 in the appropriate complete growth
media recommended by the supplier. The cell types studied were human embryonic
kidney HEK293 (ATCC, Manassas, VA), human hepatocellular carcinoma HepG2
(ATCC), primary mouse embryonic fibroblasts (PMEF) (Millipore, Manassas, VA),
and human mesenchymal stem cells (hMSC) (ATCC). All transfections were carried
out at 37uC and 5% CO2 in serum- and antibiotic-free OptiMEM (Invitrogen), which
was replacedwith the appropriate complete growthmedium4 hours after the onset of
transfection. Each transfection was performed in duplicate and quantified results
represent three independent experiments. Transfection efficiency and transgene
expression were assayed at 24 hours post-transfection. Luminescence measurements
to quantify luciferase expression were performed using the SteadyGlo kit (Promega,
Madison, WI) according to the manufacturer’s protocol.
Flow cytometry. Flow cytometric analysis was performed using a FACSCanto II (BD
Biosciences, Franklin Lakes, NJ) with at least 10,000 cells analyzed per sample. To
quantify transfection efficiency 24 hours after transfection, cells were washed briefly
with PBS without Ca21 and Mg21 (Mediatech, Washington, DC), and released from
TCPS surfaces with 0.25% Trypsin-EDTA (Invitrogen). The trypsin was inactivated
with serum-containing media and the cells were centrifuged at 4uC, resuspended in
ice-cold PBS, centrifuged again, and resuspended in PBS containing 1%
paraformaldehyde (PFA) (EMS, Hatfield, PA). The FSC/SSC was gated with
untreated cells to exclude the dead cells or cell debris. Cells transfected with non-
fluorescent pLuc plasmid served as negative controls for each equivalent pDNA or
mRNA dose, with gating such that 1% of these cells were considered GFP1.
Cellular uptake of polyplexes was evaluated in separate experiments using unla-
beled p(CBA-ABOL) polymer and QD-labeled pDNA. After predetermined post-
transfection incubation periods at 37uC, cells were washed briefly with PBS without
Ca21 and Mg21 and released from TCPS surfaces with 0.25% Trypsin-EDTA. The
trypsinwas inactivatedwith serum-containingmedia and the cells were centrifuged at
4uC, resuspended in ice-cold PBS, centrifuged again, and resuspended in PBS con-
taining 4% PFA and 2% glutaraldehyde for 15 minutes. The cells were washed with
PBS, washed again with PBS containing heparin in PBS (20 units mL21) to remove
membrane bound complexes, and then resuspended in PBS for analysis36. Timepoints
represent the elapsed time from the start of transfection until the onset of trypsini-
zation. The 405 nm laser served as the excitation source and the fluorescence emis-
sion was captured using the P10 channel (dichroric: 502 LP, emission filter: 622/
36 nm). Tomeasure rates of intracellular unpacking, cells were transfected using 154
Cy5-labeled to unlabeled polymer complexed with QD-labeled pDNA. Samples were
prepared using the same procedure described for the cellular uptake studies, however
time zerowas defined instead as the change from transfectionmedium back to growth
medium for unpacking analyses. We examined the decay of the QD-FRET emission
signal over time. Detection was accomplished by excitation with the 405 nm laser and
650 LP emission filter. The fluorescence signals were compensated and gated with
negative and single-color controls. FlowJo (v. 9.1, Tree Star, Ashland) and FACSDiva
(BD) were used to analyze the results.
Fluorescence microscopy. Epifluorescent images were captured with an inverted
fluorescence microscope (TE2000U, Nikon Instruments, Melville, NY) equipped
with a 100-W mercury arc lamp (X-Cite 120 Fluor system, EXFO, Ontario, Canada)
and a cooled CCD (CoolSnap HQ, Roper Scientific, Tucson, AZ). Monocolor
emission from GFP was collected and filtered through appropriate filters and
dichroics. Image processing and analysis was performed with ImageJ (v1.43, http://
rsb.info.nih.gov/ij).
Nanocomplex stability and free polymer measurements. Titrated volumes
PicoGreen or RiboGreen (Quant-iT, Invitrogren) reagent were added to polyplex
solutions in a 96-well plate and incubated for 15 minutes before measuring the signal
using a plate reader (BMG Labtech GmbH, Germany). To plot polyplex stability, the
background fluorescence was subtracted and the measured fluorescence intensity as
normalized to the signal in control samples containing no polymer. To quantify the
amount of unreacted polymer remaining in solution following polyplex preparation,
10 mg of polyplexes were prepared using 451 p(CBA-ABOL) to Cy5-labeled p(CBA-
ABOL90/BDA10) and centrifuged at 14,000 3 g for 30 minutes to remove the
particulate fraction. The supernatant was then collected, lyophilized then
resuspended in 100 mL complexation buffer. The suspensions were added to a 96-well
plate and the Cy5 signal was quantified. Following subtraction of the background
signal, the percentage of free polymer remaining was determined by a standard curve
constructed with titrated polymer solutions.
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Statistical analysis. Results are reported as the mean 6 S.E.M. as described for three
or more independently performed experiments. Asterisks denote p-values , 0.05.
Statistical significance was determined using an unpaired t-test (Prism 5.0, GraphPad
Software, La Jolla, CA). Two-tailed p-values are reported unless otherwise stated.
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